-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
December 2017
-
IASLC 18th WCLC Special Session Provides Overview of Updated Guidelines for Molecular Testing
Posted: December 2017 Experts in molecular testing discussed various issues on this topic in October at the IASLC 18th WCLC. Neal Lindeman, MD, led off the session with an overview of the update to the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology…
-
IASLC Consensus Statement on Liquid Biopsy
By Christian Rolfo, MD, PhD, MBAh, and Philip C. Mack, PhD Posted: December 2017 In just the past decade, tremendous advancements in the treatment of metastatic non-small cell lung cancer (NSCLC) have been made due to the identification of targetable oncogenic molecular drivers on which the tumors are dependent for their growth and survival. Precision…
-
Studies Indicate Expanding Benefit of Checkpoint Inhibitors
By Cynthia L. Kryder, MS and Lori L. Alexander, MTPW, ELS, MWC Posted: December 2017 An oral abstract session at the IASLC World Conference on Lung Cancer (WCLC) 2017 drew a standing-roomonly crowd to hear updates on studies of 3 immunotherapy drugs: pembrolizumab, nivolumab, and atezolizumab, and their role in advanced non-small cell lung cancer…
-
Bronchoscopy Ultrasound and Navigational Bronchoscopy Finally Arrive in Peru
By Luis E. Raez, MD Posted: December 2017 Under the sponsorship of the IASLC, the Peruvian Association for Bronchology and Interventional Pulmonology (APBNI) organized a seminar on bronchoscopy ultrasound (EBUS) and navigational bronchoscopy in Lima, Peru, on July 21, 2017. IASLC members Dr. Pedro Garcia-Mantilla, a pulmonologist at the Guillermo Almenara Hospital in Lima, and…
-
Cannabis, Lung Cancer, and Therapy
By Emily Stone, MBBS, MMed, FRACP, and James Jett, MD Posted: December 2017 Cannabis, a generic term for various products derived from the plant cannabis sativa, has a long history of both medicinal and recreational use. Current pressure for the regulation of cannabis use1 highlights the need for clinicians working in the areas of lung…
-
Discussing ALCHEMIST with Dr. Shakun Malik
Posted: December 2017 Patients with completely resected early-stage non-small cell lung cancer (NSCLC) have approximately a 50% chance of experiencing disease recurrence following standard treatment. In 2014, the NCI initiated a group of randomized clinical trials, called the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST), to test adjuvant treatments to prevent cancer…
-
IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology
By Jyoti Patel, MD, and Heather A. Wakelee, MD Posted: December 2017 The IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology was held September 14-16, 2017 and brought together nearly 400 participants to discuss important topics in lung cancer prevention, detection, and care. The multidisciplinary nature of the meeting was most apparent in the initial…
-
INFORMED: An Interview with Sean Khozin, MD, MPH
Posted: December 2017 The Information Exchange and Data Transformation (INFORMED) initiative was launched by the U.S. Food and Drug Administration (FDA) and the Innovation, Design, Entrepreneurship and Action (IDEA) Lab of the U.S. Department of Health and Human Services. INFORMED is intended to promote the use of big data analytics to analyze the large and…
-
Patients with EGFR Mutation Should Postpone Brain Radiation for CNS Metastases: Pro and Con
By Pranshu Mohindra, MD, MBBS, DABR®, Lecia Sequist, MD, and Laurie E. Gaspar, MD, MBA Posted: December 2017 Since the initial approval of erlotinib, an oral tyrosine kinase inhibitor (TKI), for treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC), multiple additional treatment agents targeting EGFR mutation are now…
-
Commentary Regarding Immune Checkpoint Inhibitors
By Fabrice Barlesi, MD, PhD Posted: December 2017 Since the advent of adjuvant platinumbased chemotherapy as the standard of care, little progress has been achieved in significantly improving the cure rate of patients with resected early-stage lung cancer. However, attempts to biologically drive the postoperative management of these patients to provide more precise, more effective…